Olmesartan/Amlodipine Krka (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxil, the active ingredient in Olmesartan/Amlodipine Krka, is an angiotensin II receptor blocker (ARB) presented as a fixed‑dose combination tablet for oral use. It treats hypertension, often in patients who require additional blood pressure control beyond what a single agent can provide.

GNH USA supplies Olmesartan/Amlodipine Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan/Amlodipine Krka is used in the management of cardiovascular conditions that involve elevated blood pressure. - Hypertension: provides combined blockade of the renin‑angiotensin system and calcium‑channel mediated vasoconstriction to achieve better blood‑pressure control. - High‑risk hypertension: helps patients who have not reached target blood pressure with monotherapy, reducing cardiovascular risk. - Hypertensive patients with concomitant edema: amlodipine’s vasodilatory effect counteracts fluid retention often seen with ARBs.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Peripheral edema: swelling of the ankles or feet. - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially after standing. - Flushing: transient warmth and redness. - Fatigue: general feeling of tiredness. - Palpitations: awareness of heartbeat.

Serious or Rare Side Effects: - Severe hypotension: markedly low blood pressure. - Angio‑edema: rapid swelling of lips, tongue or airway. - Hepatic dysfunction: elevated liver enzymes. - Renal impairment: worsening kidney function. - Myocardial infarction: rare but reported in susceptible patients. - Hyperkalemia: elevated potassium levels.

When prescribing Olmesartan/Amlodipine Krka, clinicians should consider several safety aspects. - Renal function: assess baseline creatinine and monitor periodically. - Hepatic function: evaluate liver enzymes before initiating therapy. - Electrolytes: check potassium levels, especially if combined with potassium‑sparing agents. - Pregnancy: avoid use; teratogenic risk is associated with ARBs. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan/Amlodipine Krka may interact with several other medicines, requiring clinical attention.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of severe hypotension, hyperkalemia and renal failure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase amlodipine plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance antihypertensive effect and cause electrolyte disturbances. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can reduce antihypertensive efficacy and affect renal function. - Lithium: concurrent use may raise lithium levels, risking toxicity. - Simvastatin: amlodipine can increase statin concentration, raising myopathy risk.